Glenmark to launch trial in solid tumours for its CD38xCD3 bispecific antibody GBR 1342
GBR 1342 is one of three investigational immuno-oncology agents based on Glenmark’s proprietary BEAT platform
Author
Strides’ subsidiary inks pact with SUDA Pharmaceuticals for migraine drug
Under the terms of agreement, SUDA will receive an upfront cash payment of $ 0.4 million and a further payment of $ 0.6 million on…
IIT Roorkee researchers develop carbon nanomaterials for detection and destruction of cancer cells
With these promising observations, Dr Gopinath and his team are planning next stage animal studies for further evaluation of these…
Lilly says diabetes drug Trulicity reduces heart risks in trial
The company did not provide any details on the magnitude of risk reduction seen in the so-called outcomes trial
bioLIVE to merge with BioProduction Congress for 2019 event
BioProduction’s content platform will be added to the bioLIVE exhibition, creating one of the world’s largest event hubs for the…
Sanofi and Regeneron’s Dupixent gets more positive feedback from US FDA
Dupixent was launched in the US in April 2017 for the treatment of moderate-to-severe eczema
The US Food & Drug…
Suven Life Sciences gets product patents from Israel, Japan
These patents are valid through 2036 and 2034 respectively
Dishman Carbogen Amcis announces successful FDA inspection
The company's site in Bavla underwent five-day inspection
Natco Pharma posts over two-fold jump in Q2 PAT to ₹ 181.6 crore
The company had posted a consolidated profit after tax of ₹ 84.4 crore in the same quarter